Inflammatory Markers and Pain in Sickle Cell Disease
ConditionSickle Cell Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
This observational cross-sectional study aims to assess the relationship between inflammatory markers and pain intensity in adult patients with sickle cell disease. The study will evaluate inflammatory markers in patients with different clinical presentations, including steady state and vaso-occlusive crisis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged ≥18 years. Confirmed diagnosis of sickle cell disease. Patients attending or admitted to the Internal Medicine Department during the study period.
Disqualifiers
Patients younger than 18 years. Acute infection or sepsis Autoimmune or chronic inflammatory diseases. Malignancy End-stage renal disease on dialysis. Chronic liver disease Blood transfusion within the preceding four weeks Recent surgery or trauma (within the preceding four weeks. Refusal to participate.
Trial population
Adult patients with confirmed sickle cell disease who present to Assiut University Hospitals during the study period. Participants will include patients in different clinical presentations, including steady state and vaso-occlusive crisis. Eligible patients will be enrolled according to the predefined inclusion and exclusion criteria.
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
75 Participants
are grouped into 1 trial groupGroup A: Adult Patients with Sickle Cell Disease
Trial outcomes
Primary outcomes
1
To determine the association between NLR, PLR, and CRP levels and pain intensity, as assessed by the Visual Analogue Scale (VAS), among adult patients with sickle cell disease.
Pain intensity will be assessed using the Visual Analog Scale (VAS), and its association with neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels will be evaluated in adult patients with sickle cell disease.
Time frame
At enrollmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: